about
sameAs
Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chipsUnderstanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatmentInhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington diseaseTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayDistinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cellsMicropublications: a semantic model for claims, evidence, arguments and annotations in biomedical communicationsSubunit composition and developmental regulation of hepatic protein phosphatase 2A (PP2A).Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experienceSignaling logic of activity-triggered dendritic protein synthesis: an mTOR gate but not a feedback switchTargeted therapy in melanoma.Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cellsTreatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.Topical rapamycin systematically suppresses the early stages of pulsed dye laser-induced angiogenesis pathways.Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosisTopical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease.From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy.Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.Inhibitors of the mammalian target of rapamycin.Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.The Enigma of Rapamycin Dosage.Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.The effect of rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal ratsModulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.PI3Kinase signaling in glioblastoma.Rapamycin-resistant effector T-cell therapy.Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.mTOR pathway: A current, up-to-date mini-review (Review).Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging.Roles of rapH and rapG in positive regulation of rapamycin biosynthesis in Streptomyces hygroscopicus.Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
P2860
Q24314346-2ABD8DFD-C687-455C-B4C4-88B8954BCE89Q28073031-74B3511E-FB41-4811-85A1-893E07EE47EFQ28261987-E5B1A1EE-311D-4C4C-9257-8871769DE3EFQ28382812-D80A87E7-BC75-4007-B64A-8AEADA29EC5AQ28509199-5C6269A2-0BE0-423D-9924-4E55532EDBC5Q28631063-FAF17C42-3B44-468D-AFDA-1C125240E8C5Q30445001-8C81D7B9-BD22-4A75-ACF3-016305E169B2Q33345588-26744215-1279-4C07-8482-84D0182AA0A1Q33365126-99E056B4-DC1A-4326-897D-223D849180CDQ33371289-C41E4E42-704F-49AC-AB35-7C9B77B20482Q33412397-EBC84AA0-1447-4F0D-8E40-AAAEE30A467AQ33573107-5085F797-B920-4008-9E0E-F1E14DC709E8Q33878961-EC5C3873-378B-4010-BC9B-965FA7985285Q33985467-05191EBA-CB3E-4999-9AF8-214690F79AEBQ34200875-01698A76-D819-4EE1-82F4-BBEF9B6A1B5FQ34381194-2C403013-9F82-4717-99F4-9082BCC5C502Q34391120-466C9EB1-0E49-4131-8A82-E84E0AA15D06Q34465141-4AC14B9C-061B-4796-BC95-2F23FDA76FD0Q34501488-2B767F8C-B725-4E34-A36B-FCAE7A44530CQ35064974-5B8B7F8B-405F-4BBE-B243-E56DF1A1989EQ35666588-45471B9F-14E2-4226-B23A-576C448BF929Q35938663-1693A371-2C12-46D9-A6BC-4AF083B26AD8Q36099427-8147A918-0632-4EF4-8E6C-F60B46A07525Q36158713-D208D21E-B6E5-41E2-9FCF-43DEC02441F2Q36184798-974273E6-99C1-4BE9-89A5-CEC620CA4F4CQ36664900-9C070AC0-A8BD-43F9-89F5-7287C61E4EF6Q36832553-04C95198-A8E9-4B2D-BEE8-A7C29E9C8918Q36842368-C74003D0-5117-4A57-BF03-834718FBEBC6Q37174984-3F0E35B4-4DAD-4D0C-BADC-947A5E864051Q37646842-83BBC7A3-1887-454F-BACD-C4A469B7D104Q37808385-D26A3E97-09E3-4246-B70D-20823E44E2ACQ38170502-7DF76188-30B5-4324-8F5A-7893D5FA840FQ38228491-692FF6F3-7238-422B-A423-D26F61A3EDE1Q38264125-0BE117EC-04EE-42FB-8B97-4DCFB90BC751Q40253260-2FDCC629-2CC4-4670-B88A-86A4CA47E274Q40665110-1BC29E2C-4459-4DC3-97F2-EFE1B8A1AE48Q42044034-701F2E4D-AE61-4DD1-A6C4-AA1F333F9412Q42077427-260883B4-D8B8-456A-BF77-667B100A5C2BQ43788777-8F2469CA-7222-4AA1-A51E-0FF84DBD689FQ46024830-1AAD41E2-8B7E-49B0-AF46-246166B0E7ED
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mechanisms of resistance to rapamycins
@ast
Mechanisms of resistance to rapamycins
@en
Mechanisms of resistance to rapamycins
@nl
type
label
Mechanisms of resistance to rapamycins
@ast
Mechanisms of resistance to rapamycins
@en
Mechanisms of resistance to rapamycins
@nl
prefLabel
Mechanisms of resistance to rapamycins
@ast
Mechanisms of resistance to rapamycins
@en
Mechanisms of resistance to rapamycins
@nl
P356
P1476
Mechanisms of resistance to rapamycins
@en
P2093
P J Houghton
P304
P356
10.1054/DRUP.2002.0227
P407
P50
P577
2001-12-01T00:00:00Z